Acute Myeloid Leukemia Clinical Trial
Intravenous (IV) Decitabine and Oral Bexarotene for Acute Myelogenous Leukemia (AML)
Summary
The main objective is to determine the safety and tolerability of combination decitabine and bexarotene during four cycles of therapy.
Full Description
The investigators are seeking to study the combination of decitabine and bexarotene. These two agents have each shown efficacy in decreasing leukemic blast counts and restoring normal hematopoiesis via different mechanisms of action and with non-overlapping side-effect profiles. By combining these agents, the investigators hope to improve overall response rates. The investigators further hope to improve platelet and neutrophil counts in an even greater number of patients, thus treating two of the most important sources of morbidity and mortality in this patient population.
Eligibility Criteria
Inclusion Criteria:
AML with bone marrow blasts ≥ 20%.
Relapsed disease after 1 or more lines of prior salvage chemotherapy and any FAB-AML, or
Diagnosis of AML and age ≥ 60 and not a candidate for cytotoxic chemotherapy and any FAB-AML except FAB-M3.
Performance status ≤ 2.
Age ≥ 18 years.
Exclusion Criteria:
Peripheral white blood cell count (WBC) > 10,000/microliter.
Total bilirubin > 1.5 x normal.
AST/ALT > 2.5 x normal.
Serum creatinine > 2 x normal.
Fasting serum triglyceride > 1,000 mg/dL.
Active or poorly controlled graft vs host disease (GVHD).
Pregnant or nursing.
Known CNS leukemia.
History of positive HIV serology.
History of positive Hepatitis C serology.
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, congestive heart failure of NYHA class 3 or 4, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements.
Chemotherapy within 21 days of enrollment.
Radiation therapy within 14 days of enrollment.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
St. Louis Missouri, 63110, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.